State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus

作者：Julie Rodriguez, Zahra Hassani, Carolina Alves Costa Silva, Fay Betsou, Federica Carraturo, Alessio Fasano, Mads Egerod Israelsen, Anandhi Iyappan, Aleksander Ahm Krag, Amira Metwaly, Robert Schierwagen, Jonel Trebicka, Hub A. E. Zwart, Joël Doré, Magali Cordaillat‐Simmons, Céline Druart, Celine Druart, Alessio Fasano, Federica Carraturo, Jonel Trebicka, Yolanda Godoy, Robert Schierwagen, Peer Bork, Anandhi Iyappan, Nassos Typas, Dienty Hendrina Maria Johanna Hazenbrink, Hub Zwart, Laurence Zitvogel, Lisa Derosa, Carolina Alves Costa Silva, Joël Doré, Hervé M. Blottière, Aïcha Kriaa, Emmanuelle Maguin, Moez Rhimi, Patrick Veiga, Nicolas Pons, Zahra Hassani, Pierre-Louis Prost, Fay Betsou, Celine Druart, Celine Druart, Magali Cordaillat-Simmons, Julie Rodriguez, Alexander Jarde, Isabelle Boutron, Philippe Ravaud, Aleksander Krag, Mads Israelsen, Ida Falk Villesen, Dirk Haller, Amira Metwaly, Paul Ross, Paul William O’Toole, Aonghus Lavelle, Marcus Joakim Claesson, Raphaela Joos, Colin Hill, Andrey Nikolaevich Shkoporov, Saba Loftus, Katy Boucher, Manimozhayan Arumugam, Arjun Sarathi, Vitalina Morozova, Nicola Segata, Francesco Asnicar, Federica Pinto · 发表于：The Lancet Microbe · 年份：2024 · DOI：10.1016/j.lanmic.2024.07.011 · 被引用次数：58 · 研究领域：Delphi Technique in Research、Gut microbiota and health、Meta-analysis and systematic reviews

Although microbiome signatures have been identified in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), qualified microbiome-based biomarkers are currently not in use in clinical practice. The Human Microbiome Action consortium initiated a Delphi survey to establish a consensus on the needs, challenges, and limitations in developing qualified microbiome-based biomarkers. The questionnaire was developed by a scientific committee via literature review and expert interviews. To ensure broad applicability of the results, 307 experts were invited to participate; 114 of them responded to the first round of the survey, 93 of whom completed the second and final round as well. The survey highlighted the experts' confidence in the potential of microbiome-based biomarkers for several indications or pathologies. The paucity of validated analytical methods appears to be the principal factor hindering the qualification of these biomarkers. The survey also showed that clinical implementation of these biomarkers would only be possible if kitted and validated molecular assays with simple interpretation are developed. This initiative serves as a foundation for designing and implementing public-private collaborative projects to overcome the challenges and promote clinical application of microbiome-based biomarkers.